Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor Apremilast

被引：22
|
作者：
Krase, Ifat Zerin [1 ]
Cavanaugh, Kevin [2 ]
Curiel-Lewandrowski, Clara [2 ]
机构：
[1] Univ Arizona, Coll Med, Tucson, AZ 85724 USA
[2] Univ Arizona, Dept Dermatol, 1501 N Campbell Ave, Tucson, AZ 85724 USA
来源：
JAMA DERMATOLOGY | 2016年 / 152卷 / 03期
关键词：
D O I：
10.1001/jamadermatol.2015.3405
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：348 / 350
页数：4
相关论文
共 50 条
  • [31] Pharmacological activity of difamilast, a novel PDE4 inhibitor for the topical treatment of atopic dermatitis: Comparison with other PDE4 inhibitors
    Hiyama, Hidetaka
    Arichika, Naoya
    Sakurai, Kazushi
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB255 - AB255
  • [32] Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
    Mease P.J.
    Rheumatology and Therapy, 2014, 1 (1) : 1 - 20
  • [33] Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4)
    Cameron, Ryan T.
    Coleman, Ryan G.
    Day, Jon P.
    Yalla, Krishna C.
    Houslay, Miles D.
    Adams, David R.
    Shoichet, Brian K.
    Baillie, George S.
    BIOCHEMICAL PHARMACOLOGY, 2013, 85 (09) : 1297 - 1305
  • [34] Efficacy of ustekinumab and guselkumab in treatment refractory pityriasis rubra pilaris: A case series
    Pham, James P.
    Allen, Nicholas
    Smith, Annika
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 (04) : 522 - 524
  • [35] Preclinical Pharmacokinetics of PDE-310, a Novel PDE4 Inhibitor
    Song, Jin Sook
    Rho, Hyeong Jin
    Park, Jong Shik
    Kim, Min Sun
    Lee, Byung Hoi
    Seo, Jeong-won
    Jeon, Dong Ju
    Cheon, Hyae Gyeong
    Ahn, Sung Hoon
    Kwon, Kwang-il
    Bae, Myung Ae
    DRUG METABOLISM AND PHARMACOKINETICS, 2011, 26 (02) : 192 - 200
  • [36] Pharmacology of a Novel, Orally Active PDE4 Inhibitor
    Dastidar, Sunanda G.
    Ray, Abhijit
    Shirumalla, Rajkumar
    Rajagopal, Deepa
    Chaudhary, Shiwani
    Nanda, Kamna
    Sharma, Pawan
    Seth, Mahesh Kumar
    Balachandran, Sarala
    Gupta, Nidhi
    Palle, Venkata
    PHARMACOLOGY, 2009, 83 (05) : 275 - 286
  • [37] PDE4 Gene Family Variants Are Associated with Response to Apremilast Treatment in Psoriasis
    Liadaki, Kalliopi
    Zafiriou, Efterpi
    Giannoulis, Themistoklis
    Alexouda, Sofia
    Chaidaki, Kleoniki
    Gidarokosta, Polyxeni
    Roussaki-Schulze, Angeliki-Viktoria
    Tsiogkas, Sotirios G.
    Daponte, Athina
    Mamuris, Zissis
    Bogdanos, Dimitrios P.
    Moschonas, Nicholas K.
    Sarafidou, Theologia
    GENES, 2024, 15 (03)
  • [38] The phosphodiesterase 4 (PDE4) inhibitor roflumilast improves remyelination in a mouse model for multiple sclerosis
    Schepers, M.
    Mailleux, J.
    Bogie, J.
    van Goethem, N.
    Hellings, N.
    Hendriks, J.
    Prickaerts, J.
    Vanmierlo, T.
    GLIA, 2017, 65 : E361 - E361
  • [39] Effectiveness of roflumilast, a phosphodiesterase type-4 (PDE4) inhibitor on biomarkers of inflammation in COPD
    Savelikhina, Iryna
    Ostrovskyy, Mykola
    Zuban, Alla
    Varunkiv, Oleksandr
    Kulynych-Miskiv, Mariana
    Shvets, Kostiantyn
    Korzh, Galyna
    Makoyda, Iryna
    Korzh, Nadiia
    Shevchuk-Budz, Uliana
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [40] In vitro and in vivo metabolism of CHF 6001, a selective phosphodiesterase (PDE4) inhibitor
    Cenacchi, Valentina
    Battaglia, Rosangela
    Cinato, Flavio
    Riccardi, Benedetta
    Spinabelli, Daniele
    Brogin, Giandomenico
    Puccini, Paola
    Pezzetta, Daniele
    XENOBIOTICA, 2015, 45 (08) : 693 - 710
12345